DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids neither replicate nor elicit vector-directed immune responses in hosts. While earlier work found the immune responses induced by DNA vaccines to be sub-optimal in larger mammals and humans, recent developments in key synthetic DNA and electroporation delivery technologies have now allowed DNA vaccines to elicit significantly more potent and consistent responses in several clinical studies. This paper will review findings from the recent clinical and preclinical studies on DNA vaccines targeting emerging infectious diseases (EID) including COVID-19 caused by the SARS-CoV-2 virus, and the technological advancements pivotal to the improved responses—including the use of the advanced delivery technology, DNA-encoded cytokine/mucosal adjuvants, and innovative concepts in immunogen design. With continuous advancement over the past three decades, the DNA approach is now poised to develop vaccines against COVID-19, as well as other EIDs.
【저자키워드】 COVID-19, SARS-CoV-2, Coronaviruses, DNA vaccines, intradermal electroporation, emerging infectious diseases (EIDs), DNA-launched nanoparticle vaccines, intranasal vaccines, 【초록키워드】 Vaccine, immune response, vaccination, adaptive, Immunity, adjuvants, Infectious disease, DNA, humans, response, Clinical studies, in vivo, DNA vaccine, safety profile, preclinical study, Electroporation, antigenic, hosts, while, approach, DNA plasmid, develop, caused, significantly more, replicate, elicit, mammal, the SARS-CoV-2 virus, 【제목키워드】 technology, Infectious disease, DNA, Rapid, development, Other, synthetic, advance, recent, Against,